EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved

Angel Justiz-Vaillant, Sachin Soodeen, Odalis Asin-Milan, Julio Morales-Esquivel, Rodolfo Arozarena-Fundora

Immuno · 26.05.2025 · 5 (2) · 18

DOI: 10.3390/immuno5020018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno, online erschienen am 26.05.2025. Verfasst von Angel Justiz-Vaillant und 4 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review aims to explore the role of immunotherapeutic strategies—primarily intravenous immunoglobulin (IVIG), plasma exchange (PLEX), and selected immunomodulatory agents—in the treatment of neurological and psychiatric disorders with suspected or confirmed autoimmune mechanisms. A central focus is placed on understanding the immunopathology of these conditions through the identification and characterization of disease-associated autoantibodies. Disorders such as autoimmune encephalitis, myasthenia gravis, limbic epilepsy, neuropsychiatric systemic lupus erythematosus (NPSLE), and certain forms of schizophrenia have shown clinical responses to immunotherapy, suggesting an underlying autoimmune basis in a subset of patients. The review also highlights the diagnostic relevance of detecting autoantibodies targeting neuronal receptors, such as NMDA and AMPA receptors, or neuromuscular junction components, as biomarkers that guide therapeutic decisions. Furthermore, we synthesize findings from published randomized controlled trials (RCTs) that have validated the efficacy of IVIG and PLEX in specific diseases, such as Guillain–Barré syndrome, and myasthenia gravis. Emerging clinical evidence supports expanding these treatments to other conditions where autoimmunity is implicated. By integrating immunological insights with clinical trial data, this review offers a comprehensive perspective on how immunotherapies may be tailored to target autoimmune contributors to neuropsychiatric disease.

Zitieren

APA

Justiz-Vaillant, A., Soodeen, S., Asin-Milan, O., Morales-Esquivel, J., & Arozarena-Fundora, R. (2025). Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved. Immuno, 5(2), 18. https://doi.org/10.3390/immuno5020018

Vancouver

Justiz-Vaillant A, Soodeen S, Asin-Milan O, Morales-Esquivel J, Arozarena-Fundora R. Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved. Immuno. 2025;5(2):18. doi:10.3390/immuno5020018

BibTeX
@article{JustizVaillant2025,
  author = {Justiz-Vaillant, Angel and Soodeen, Sachin and Asin-Milan, Odalis and Morales-Esquivel, Julio and Arozarena-Fundora, Rodolfo},
  title = {Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved},
  journal = {Immuno},
  year = {2025},
  volume = {5},
  number = {2},
  pages = {18},
  doi = {10.3390/immuno5020018}
}
Kostenlos starten →